Selegiline Patent Expiration
Selegiline was first introduced by Somerset Pharmaceuticals Inc
Selegiline Patents
Given below is the list of patents protecting Selegiline, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Emsam | US7150881 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
Jun 12, 2018
(Expired) | Somerset |
| Emsam | US7070808 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
May 10, 2018
(Expired) | Somerset |
| Emsam | US7638140 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
May 10, 2018
(Expired) | Somerset |
Selegiline's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Selegiline:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects | Corium Innovations, Inc. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects | Corium Innovations, Inc. | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |